IL-12Rβ2 is Expressed in the Synthetic SMC and Detected in the Blood of Patients With Acute Myocardial Infarction Authors: Dong Hoon Kang, Hee Su Lee, Jin-Ah Yang, In Sook Kang, Sodam Jung, Kihwan Kwon, Sang Won Kang Published: 2026 ABSTRACT Author's summaryCurrent cardiac biomarkers fail to detect vascular smooth muscle cell (SMC) activation, a key feature of vulnerable plaque formation in acute myocardial infarction (AMI). This study identifies interleukin-12 receptor beta 2 subunit (IL-12Rβ2) as a receptor selectively expressed in synthetic SMCs upon interferon-γ stimulation and released via SMC-derived extracellular vesicles. Circulating IL-12Rβ2 was significantly elevated in AMI patients and detected using a novel capture enzyme-linked immunosorbent assay. These findings suggest IL-12Rβ2 as a non-invasive biomarker reflecting SMC-driven plaque instability, offering a novel diagnostic strategy for early risk stratification in coronary artery disease.Keywords: Interleukin-12 receptor beta 2 subunit, Smooth muscle cells, Myocardial infarction, Extracellular vesicle, Biomarker INTRODUCTION Atherosclerosis is the primary cause of ischemic heart disease due to coronary arterial occlusion and rupture.1) The early stages of atherosclerosis are characterized by sub-endothelial accumulations of lipid-laden macrophages, also known as foam cells, which form initial ‘fatty streak’ lesions.2) Over time, these evolve into fibrous plaques containing lipid-rich necrotic cores, surrounded by proliferating smooth muscle cells (SMCs) and extracellular matrix. This complex remodeling thickens and stiffens the arterial wall, forming mature plaques that progressively narrow the lumen. Once unstable, plaques may rupture, releasing pro-thrombotic material that can trigger thrombosis and lead to acute events such as myocardial infarction (AMI) or stroke.3) Atherosclerotic changes in coronary arteries usually progress slowly and often remain asymptomatic until they cause significant luminal narrowing or plaque rupture.4) AMI typically presents suddenly and demands immediate intervention, such as percutaneous coronary intervention, to limit myocardial damage.5) Therefore, early diagnosis of unstable and vulnerable plaques, which sooner or later definitely causes AMI,6) is crucial for reduction of sudden death. Current blood biomarkers useful for detection of cardiovascular disease (CVD) are mostly associated with lipid, cardiac dysfunction, and inflammation. These include lipoprotein, troponin, B-type natriuretic peptides (BNPs), and C-reactive protein (CRP).7),8),9) Longitudinal studies, such as the Framingham Heart Study, have conducted extensive follow-ups on thousands of participants to evaluate the utility of multiple biomarkers in predicting CVD risk. These studies have targeted 85 high-value proteins related to CVD, encompassing markers that represent various pathophysiological pathways.10) Proteomics and metabolomics approaches have also been attempted to identify circulating biomarkers that correlate with disease progression.11),12) However, the clinical translation has been limited by inter-individual variability and the inaccessibility of human arterial tissues with early stages of atherosclerosis. To overcome these limitations, we previously conducted a differential proteomics using rat carotid arteries of balloon injury model, which selectively reflects the neointimal SMC hyperplasia following endothelial denudation.13) Recently, we noted an intriguing protein identified as interleukin -12 receptor β2 (IL-12Rβ2, gene locus IL-12RB2), which was missed in the previous analysis because it is an immune cell receptor expressed in natural killer and T cells. We hypothesized that IL-12Rβ2 might be induced in SMCs in a phenotype-dependent manner and contribute to proliferation and migration of the de-differentiated SMCs. In this study, we characterized the IL-12Rβ2 expression in human aortic SMC (HASMC). Surprisingly, IL-12Rβ2 expression was induced by a pro-atherogenic cytokine interferon-γ (IFN-γ) and phenotypic change in the cultured HASMCs. The depletion of IL-12Rβ2 expression inhibited the proliferation and migration of HASMCs. Moreover, we found that IL-12Rβ2 was present in the SMC-liberating extracellular vesicles (EVs) isolated from plasma samples of human patients with AMI. For a clinically relevant biomarker study, we developed a capture enzyme-linked immunosorbent assay (ELISA) system containing anti-platelet-derived growth factor beta chain (PDGFRβ) antibody as a SMC-specific capture antibody and anti-IL-12Rβ2 antibody as a detection antibody. The subsequent screening with clinically validated plasma samples demonstrated that IL-12Rβ2 levels are selectively elevated in AMI patients compared to healthy volunteers and patients with stable angina (SA). Hence, plasma EV-associated IL-12Rβ2 can be a novel biomarker for early detection of atherosclerotic lesions with vulnerable plaques containing proliferating synthetic-type SMCs. METHODS Ethical statement This study was approved by the Institutional Review Board (IRB) of Ewha Womans University Medical Center (No. 2019-10-017). Written informed consent was obtained from all participants in accordance with the latest version of the Declaration of Helsinki. Animal experiments were performed in compliance with the guidelines of the Institutional Animal Care and Use Committee of Ewha Womans University (No. 24-077). Histological analysis Rats were anesthetized with a mixture of isoflurane gas (N2O2/70%:30%) and underwent transcardiac perfusion-fixation with heparinized saline containing 3.7% formaldehyde. Following fixation, the common carotid arteries were excised, paraffin-embedded, and sectioned using a rotary microtome (Leica RM2255; Leica, Wetzlar, Germany). Two serial tissue sections, each 4 μm in thickness, were obtained from the middle region of the common carotid arteries and stained with hematoxylin and eosin. The luminal area, internal elastic lamina, and external elastic lamina were measured using National Institutes of Health (NIH) Image software (v1.62; NIH, Bethesda, MD, USA). The intimal and medial areas were calculated by subtracting the luminal area from the internal elastic lamina and the internal elastic lamina from the external elastic lamina, respectively. The values from 2 serial sections per rat were averaged for quantitative analysis. Isolation of extracellular vesicles Plasma samples were subjected to EV isolation using the ExoQuick Ultra EV Isolation Kit (System Biosciences, Palo Alto, CA, USA) according to the manufacturer’s instructions. Isolated EVs were validated by either immunoblot analysis using an antibody against the EV marker CD81 or nanoparticle tracking analysis (NTA) on a Nano SAQRA. Analysis of human blood specimen Blood specimens were collected from healthy volunteers and patients with angiographically confirmed coronary artery disease, as approved by the IRB of Ewha Womans University Medical Center (Seoul, Korea). The patients with coronary artery disease who had ischemic symptoms were classified as SA, and AMI according to clinical criteria. All volunteers participated in this study after providing informed consent. Whole blood samples were centrifuged to separate plasma, and the plasma was further processed for analysis. To prepare the samples for immunoblotting, plasma was clarified using the Pierce Albumin/IgG Removal Kit® (Thermo Fisher Scientific, Waltham, MA USA), following the manufacturer’s protocol, to remove high-abundance proteins and enhance the detection of target proteins. Sandwich enzyme-linked immunosorbent assay for plasma platelet-derived growth factor beta chain The 96-well microplates were coated with anti-PDGFRβ antibody (clone No. P050, 1 µg/mL) in carbonate buffer (pH 9.6) and incubated overnight at 4°C. After washing twice with phosphate-buffered saline (PBS) containing 0.05% Tween-20 (PBST), the wells were blocked with 1% casein in PBS at 4°C overnight to minimize non-specific binding. Then, plasma samples (100 µL) were added to the PDGFRβ antibody-coated wells and incubated for 1 hour at 37°C. After washing 3 times with PBS, each well was incubated with a biotin-conjugated anti-PDGFRβ antibody (0.5 µg/mL in PBST containing 1% casein) for 1 hour at 37°C. After washing 3 times with PBST, horseradish peroxidase (HRP)-streptavidin was added and incubated for 1 hour at 37°C. The colorimetric signal was developed using TMB substrate (Thermo Fisher Scientific), stopped with 1N H2SO4, and the absorbance was measured at 450 nm using a microplate reader. Capture enzyme-linked immunosorbent assay for plasma interleukin-12 receptor β2 The 96-well microplates were coated with anti-PDGFRβ antibody (clone No. P050, 1 µg/mL) in carbonate buffer (pH 9.6) and incubated overnight at 4°C. After washing twice with PBST, the wells were blocked with 1% casein in PBS overnight at 4°C and again washed 3 times with PBST. The aliquots of plasma samples (100 µL) were added to the PDGFRβ antibody-coated wells and incubated for 1 hour at 37°C, allowing specific binding of SMC-derived EVs to the PDGFRβ antibody. Afterward, the wells were washed 5 times with PBST and incubated with the biotin-conjugated anti-IL-12Rβ2 antibody (0.5 µg/mL in PBST containing 1% casein) for 1 hour at 37°C. After washing 5 times with PBST, HRP-conjugated streptavidin beads were added to the wells and incubated for 1 hour at 37°C. The colorimetric signal was developed using TMB substrate, stopped with 1N H2SO4, and the absorbance was measured at 450 nm using a microplate reader. The diagnostic sensitivity and specificity of the capture ELISA were calculated by comparing the proportion of correctly classified samples among AMI patients (true positives) and non-AMI controls, which included both normal individuals and patients with SA (true negatives). Specifically, sensitivity (%) was calculated as Specifically, sensitivity (%) was calculated as [True Positives/(True Positives+False Negatives)]×100, and specificity (%) as [True Negatives/(True Negatives+False Positives)]×100. Statistical analysis Data were analyzed with either Student’s t-test for comparisons between 2 groups or one-way analysis of variance with Tukey’s ‘honestly significant difference’ post hoc test for multiple groups (SPSS 12.0K for Windows; SPSS, Chicago, IL, USA) to determine the statistical significance (p value). A p<0.05 was statistically significant. Data for blood specimens were analyzed with 2 non-parametric tests: Kruskal-Wallis rank sum test and Wilcoxon rank sum test. Detailed experimental protocols, including cell culture conditions, small interfering RNA (siRNA) transfection, quantitative real-time polymerase chain reaction (qPCR) primer sequences, western blotting, flow cytometry, and balloon-induced carotid artery injury in rats, are provided in Supplementary Data 1. RESULTS Upregulation of interleukin-12 receptor β2 in the occluded arteries We previously performed proteomic screening to identify the differentially expressed proteins in a balloon-injured rat carotid arteries by 2-dimensional difference gel electrophoresis 13) Among the identified proteins, we noted an unexpected protein spot corresponding to IL-12Rβ2, a receptor typically expressed in immune cells (Supplementary Figure 1). Immunoblot analysis using a polyclonal antibody (clone No. N3C2) specific for rat IL-12Rβ2 protein confirmed that the IL-12Rβ2 expression was markedly upregulated 7 days after a balloon injury (Figure 1A). To evaluate the clinical relevance of this finding, we performed immunohistochemistry staining of this receptor on human carotid arterial sections with atherosclerotic lesions. IL-12Rβ2 protein levels were approximately 2-fold higher in the occluded atherosclerotic lesions compared to normal peripheral arteries (Figure 1B). Notably, the strong positive signals were observed throughout the thickened medial layers and largely incorporated in the migrating SMCs as indicated in the high-magnification images (Figure 1C). These unexpected results prompted us to further investigate IL-12Rβ2 expression in SMCs. Increased expression of IL-12Rβ2 in carotid arteries from balloon-injured rats and human patients with atherosclerotic lesions. (A) Neointimal thickening and IL-12Rβ2 expression in sham-operated control and balloon-injured rat carotid arteries at 7 days post injury. Representative hematoxylin and eosin images of sham-operated and 7-day post-injury arteries are shown. The vascular lumen (L) and neointimal layer (arrow) are indicated. The tissue extracts of rat carotid arteries were subjected to immunoblot analysis with anti-rat IL-12Rβ2 antibody. (B) Immunohistochemistry analysis of human carotid artery sections with atherosclerotic lesions. The IL-12Rβ2-positive DAB intensities were quantified in 2 different lesions (dashed box). The DAB intensities were averaged and expressed as the fold increase of the IL-12Rβ2 expression relative to normal tissue. The patient identification numbers and vascular lumen (L) are indicated. (C) High-magnification images of IL-12Rβ2 expression in atherosclerotic lesions. Enlarged views of atherosclerotic lesions show distinct IL-12Rβ2 localization in migrating SMCs (arrowhead) in the thickened medial layer. The arrow denotes the direction toward the lumen. DAB = 3,3’-diaminobenzidine; IL-12Rβ2 = interleukin-12 receptor beta2 subunit; SMC = smooth muscle cell. Interleukin-12 receptor β2 expression is induced by interferon-γ in the human aortic smooth muscle cell Analysis of the NCBI database revealed 7 transcript variants of the IL-12Rβ2 gene with different exon structures. To address which variant is expressed in SMCs, we designed the primer sets for qPCR capable of distinguishing each variant (Supplementary Figure 2A). As IL-12Rβ2 is commonly expressed in immune cell types, we first validated the primer sets in U937 human monocytic cells. The results showed that U937 cells mainly express the IL-12Rβ2 variant 1 (Supplementary Figure 2B). However, qPCR analysis of mRNAs extracted from confluent HASMCs showed no detectable IL-12Rβ2 expression. We then screened various cytokines relevant to vascular inflammation to seek any possible inducer. Unexpectedly, the IL-12Rβ2 expression was remarkably induced in the HASMCs by treatment of IFN-γ (Figure 2A). In contrast, none of the other cytokines, such as IL-12, tumor necrosis factor (TNF)-α, and IL-1β, induced a detectable upregulation of IL-12Rβ2 expression in HASMCs. The mRNA levels induced by IFN-γ in HASMC were comparable to the basal IL-12Rβ2 level in U937 cells (Figure 2B). Additional qPCR assays using 2 different primer sets further confirmed that IFN-γ-treated HASMCs expressed IL-12Rβ2 variant 1 (Supplementary Figure 2C). To verify whether the variant induced in HASMCs is identical to that in U937 cells, we cloned and sequenced the full-length IL-12Rβ2 cDNA from both cell types. Interestingly, the HASMC-expressed IL-12Rβ2 gene had only one amino acid substitution (G465D) compared to the U937-harboring gene (Supplementary Figure 2D), which means that both cell types express the same variant gene. IFN-γ-induced and phenotypic expression of IL-12Rβ2 in HASMCs. (A) Quantitative PCR analysis of IL-12Rβ2 mRNA levels in HASMCs treated with IFN-γ, IL-12, TNF-α, and IL-1β for the indicated times. Data in graphs are means ± SD of relative fold changes versus untreated samples (n=3). (B) RT-PCR products showing full-length IL-12Rβ2 cDNAs in the IFN-γ-treated HASMCs and U937 monocytic cells. The PCR products were subjected to the nucleotide sequencing. (C) Immunoblot analysis of U937 cell lysates with anti-human IL-12Rβ2 antibody (clone No. 2H6). U937 cells were transfected with either luciferase (CONT) or IL-12Rβ2 siRNA for 24 hours. Arrowhead indicates the IL-12Rβ2-specific band. (D) Flow cytometry analysis showing IL-12Rβ2 protein expression increased in HASMCs treated with IFN-γ (n=3). (E) Cell density-dependent IL-12Rβ2 expression in HASMCs. HASMCs were seeded at LD (8×103 cells/cm2) and HD (1×106 cells/cm2). Data in the graph are means ± SD of relative fold change (n=4). CONT = control; HASMC = human aortic smooth muscle cell; HD = high density; IFN = interferon; IL = interleukin; IL-12Rβ2 = interleukin-12 receptor beta 2 subunit; LD = low density; PCR = polymerase chain reaction; RT-PCR = reverse transcription-polymerase chain reaction; SD = standard deviation; TNF = tumor necrosis factor. **p<0.01; ***p<0.001. We next examined whether the IL-12Rβ2 transcript induced by IFN-γ indeed produce the membrane-associated receptor protein. To do so, we chose an antibody (clone 2H6) recognizing the extracellular domain of human IL-12Rβ2 and validated its specificity in U937 human monocyte lymphoma cells transfected with IL-12Rβ2-specific siRNA. Western blot analysis clearly indicated that the antibody (clone 2H6) recognized the IL-12Rβ2-specific band, which disappeared following siRNA-mediated knockdown (Figure 2C). Flow cytometry analysis using this specific antibody revealed that IFN-γ treatment induced nearly a ten-fold increase in surface IL-12Rβ2 expression in HASMCs (Figure 2D), supporting the functional expression of this receptor in SMCs. To assess whether IL-12Rβ2 expression correlates with SMC phenotypic state, we cultured HASMCs at low and high densities to induce synthetic and contractile phenotypes, respectively.14),15) The qPCR analysis showed that the synthetic SMCs grown at low density strongly induced the IL-12Rβ2 expression compared to the contractile SMCs grown at high density (Figure 2E). These results suggest that IL-12Rβ2 is selectively expressed in de-differentiated, synthetic SMCs that proliferate and migrate in diseased arterial walls. Collectively, this represents the first evidence of IL-12Rβ2 expression in the non-immune cells, particularly in synthetic SMCs. Interleukin-12 receptor β2 is functionally active in smooth muscle cells and arterial vessels Next, we evaluated the functional role of IL-12Rβ2 in synthetic SMCs by both in vitro and in vivo experiments. For in vitro study, IL-12Rβ2 expression was silenced by a specific siRNA in low-confluent HASMCs. The cell-based assays demonstrated that IL-12Rβ2 knockdown significantly reduced PDGF-BB-stimulated proliferation and migration (Figure 3A and B). Moreover, TNF-α-induced monocyte adhesion to HASMCs was markedly inhibited by IL-12Rβ2 silencing (Figure 3C), suggesting that IL-12Rβ2 may functionally cooperate with other receptors involved in synthetic SMC activation after de-differentiation. To further evaluate the significant role of IL-12Rβ2 in vivo, we operated the balloon injury model in the rat carotid arteries where IL-12Rβ2 expression was depleted by a catheter-mediated intramural delivery of IL-12Rβ2 siRNAs, as described in the Supplementary Data 1. Histological analysis at 10 days post-injury revealed that IL-12Rβ2 depletion significantly inhibited the injury-induced neointimal thickening compared to that of the control samples (Figure 3D). Consistently, the qPCR analysis confirmed both the injury-induced upregulation of IL-12Rβ2 and its successful depletion by the specific siRNA (Figure 3E). These findings provide compelling evidence that IL-12Rβ2 actively functions in the SMC hyperplasia during vascular remodeling. Functional validation of IL-12Rβ2 in HASMCs and rat carotid arteries. (A-C) HASMCs were transfected with either luciferase (CONT) or IL-12Rβ2 siRNA for 24 hours and stimulated with PDGF-BB (25 ng/mL) or TNF-α (10 ng/mL) for additional 24 hours. Cell proliferation (A), migration (B), and monocyte adhesion (C) were measured as described in the Methods section. Data in the graphs are means ± SD of relative fold changes versus untreated samples (n=3). (D) Effects of IL-12Rβ2 knockdown on neointimal hyperplasia. A representative histological image of rat carotid arteries at 10 days post-injury is shown. Data are presented as violin plots with individual data, showing means ± standard error of the mean of the intima-media ratio (n=7 or 9 per group). (E) Knockdown of IL-12Rβ2 expression by in situ transfection of IL-12Rβ2-specific siRNA in rat carotid arteries. Data in the graphs are means ± SD of relative fold changes versus control luciferase siRNA group (n=4). CONT = control; HASMC = human aortic smooth muscle cell; IL-12Rβ2 = interleukin-12 receptor beta2 subunit; PDGF-BB = platelet-derived growth factor-BB; SD = standard deviation; si- = small interfering; TNF = tumor necrosis factor. *p<0.05; **p<0.01. Interleukin-12 receptor β2 is detected in the blood plasma of human patients with acute myocardial infarction Given that IFN-γ is a key cytokine orchestrating the SMC phenotypic switching and vascular remodeling,16) we thought that IFN-γ-induced IL-12Rβ2 expression in the synthetic SMCs has a clinical significance relevant to atherosclerosis. Furthermore, it is known that the proliferating and migrating SMCs are exposed to lumen during vulnerable plaque progression and the EVs play multifaceted roles in atherosclerosis.17) Thus, we hypothesized that they could liberate the EVs containing newly expressed and membrane-targeted IL-12Rβ2. To assess this hypothesis, we first analyzed plasma samples collected from healthy volunteers (n=16), patients with SA (n=19), and patients with AMI (n=19). The clinical characteristics of the healthy volunteers and patients taking part in a pilot-scale study were clearly defined by cardiology specialists (Supplementary Table 1). Notably, standard cardiac-derived biomarkers such as troponin-T and creatine kinase-MB were significantly higher in the AMI patients than in the healthy volunteers and SA patients. Prior to immunoblot analysis, abundant plasma proteins including albumin and immunoglobulins were depleted using dye-affinity Cibacron Blue beads (Figure 4A, Supplementary Figure 3A). Subsequent immunoblotting showed that IL-12Rβ2 levels were significantly elevated in the plasma samples from AMI patients compared to those from healthy volunteers and SA patients (Figure 4B, Supplementary Figure 3B). In contrast, none of the other intracellular proteins, which had been shown to be elevated in occluded carotid arteries of human patients with atherosclerosis,13) were detected in any plasma samples (Supplementary Figure 3C), suggesting that IL-12Rβ2 might be a potential blood biomarker associated with vulnerable plaques in atherosclerotic lesions. Detection of IL-12Rβ2 in plasma extracellular vesicles isolated from the blood of human patients with acute coronary syndromes. (A) High abundant plasma proteins (albumin and immunoglobulins) were clarified from human plasma samples using a mixture of Cibacron Blue Dye and Protein-A affinity agarose resins (albumin/Ig removal kit). Lane 1, plasma sample; lane 2, Resin-bound fraction; lane 3, Unbound filtrate. The unbound filtrates were used for the following studies. The plasma samples are labeled by patient IDs. The acrylamide gels were stained by Coomassie Blue R-250. Representative gels shown contain 4 representative samples for each cohort. The sample information is summarized in Supplementary Table 1 (Normal: n=16, 60.8±11.9 years old; SA: n=19, 62.0±11.3 years old; AMI: n=19, 64.6±11.6 years old). (B) IB analysis of IL-12Rβ2 protein in the clarified human plasma samples. The IL-12Rβ2-specific bands were quantified and normalized by protein amount loaded per lane. Data in the graph is mean intensities ± standard deviation. The nitrocellulose membranes were stained with Ponceau S to see the equal loading. A representative blot shown contains 4 representative samples for each cohort. (C) IB analysis of EVs isolated from the clarified human plasma samples (10 mg) by the polymer-based precipitation. The resulting Sup. and EV-containing precipitates were loaded at equal amount and immunoblotted with indicated antibodies. A representative IB is shown (n=3). (D, E) Co-localization of PDGFRβ and IL-12Rβ2 in the plasma EVs. EVs were immunoprecipitated from the clarified plasma samples (5 mg of total protein) using either anti-CD81 (D) or anti-PDGFRβ (E) antibody and analyzed by immunoblotting. A representative IB is shown (n=3). AMI = acute myocardial infarction; CD81 = cluster of differentiation 81; EV = extracellular vesicle; IB = immunoblot; IL-12Rβ2 = interleukin-12 receptor beta2 subunit; IP = immunoprecipitation; n.s. = not significant; PDGFRβ = platelet-derived growth factor beta chain; PonS = Ponceau S; SA = stable angina; Sup. = supernatants. *p<0.05; ###p<0.005. Since the full-length form of IL-12Rβ2 was detected in the plasma samples, we presumed that the plasma IL-12Rβ2 may be associated with EVs rather than proteolytic shedding.18),19) To confirm this, EVs were isolated from plasma samples using a polymer-based precipitation method.20) To validate the EV preparation, we then performed NTA of the EV fraction isolated from a representative plasma sample (patient #28). The NTA data demonstrated a unimodal particle size distribution with a predominant peak around 120 nm and a polydispersity index of 0.271 (Supplementary Figure 4), indicating a moderately uniform vesicle population consistent with the expected size range of EVs. The particle concentration was approximately 1.4×1013 particles/mL. Indeed, IL-12Rβ2 was detected in the EV samples which had been isolated from the plasma samples from AMI patients, along with the canonical EV marker CD81 (Figure 4C). Notably, PDGFRβ as the synthetic SMC-specific membrane receptor was also enriched in the same EV fractions, indicating that the fractions contain the SMC-derived EVs. To further verify that IL-12Rβ2 and PDGFRβ are co-localized in the same EVs, we immunoprecipitated the EVs using anti-CD81 antibody. Indeed, both IL-12Rβ2 and PDGFRβ were detected in the EVs isolated from the plasma samples of AMI patients using anti-CD81 antibody, but not those isolated from the plasma samples of healthy volunteers (Figure 4D). Subsequent immunoprecipitation of these EVs using an anti-PDGFRβ antibody confirmed that IL-12Rβ2, PDGFRβ, and CD81 were co-enriched in the same SMC-derived EVs (Figure 4E). Taken together, these findings indicate that IL-12Rβ2- and PDGFRβ-positive EVs are liberated from proliferating SMCs within vulnerable atherosclerotic plaques into the circulation. Non-invasive diagnosis of acute myocardial infarction with an extracellular vesicle-capturing enzyme-linked immunosorbent assay To enable large-scale analysis of SMC-derived EVs, we developed a capture ELISA system containing anti-human PDGFRβ antibody for capturing EVs and anti-human IL-12Rβ2 antibody for detection (Figure 5A). This novel capture ELISA system, along with the standard sandwich ELISA system, was tested using a pilot set of plasma samples previously characterized by immunoblotting as shown above. First, the sandwich ELISA assay using paired human PDGFRβ-specific antibodies demonstrated that PDGFRβ protein levels were nearly undetectable in the plasma samples from healthy volunteers (n=12) but markedly elevated in those from both SA (n=11) and AMI patients (n=15) (Figure 5B). Of note, this result strongly suggests that medial SMCs are shielded from the bloodstream by endothelium in healthy arterial walls, whereas neointimal synthetic SMCs are exposed and release EVs to lumen. Then, we performed the capture ELISA assay containing 2 different antibodies against PDGFRβ and IL-12Rβ2. Surprisingly, IL-12Rβ2 levels in the captured SMC-derived EVs were comparable each other in plasma samples of healthy volunteers and SA patients, which indicates that the SMCs stabilized in the thickened neointimal layer do not express the IL-12Rβ2, possibly due to the absence of IFN-γ stimulation.21),22) In contrast, the IL-12Rβ2 levels in the captured SMC-derived EVs were pretty much higher in the plasma samples from AMI patients (n=22) than those from healthy volunteers (n=15) and SA patients (n=21) (Figure 5C). We further repeated the capture ELISA assay with a total of 219 plasma samples from 3 groups (Healthy; n=71, SA; n=77, and AMI; n=71). Consistently, the assay and statistical analysis confirmed that levels of IL-12Rβ2 protein associated with the SMC-derived EVs captured by anti-PDGFRβ antibody were markedly elevated in the plasma samples from AMI patients, while the IL-12Rβ2 levels were nearly undetectable at baseline in those from healthy volunteers and SA patients (Figure 5D). In addition, we validated the quantitative accuracy of our capture ELISA system by a dilution linearity using a simple fusion peptide containing the 2 epitope regions recognized by anti-PDGFRβ and anti-IL-12Rβ2 antibodies. As a result, serial dilutions of the fusion peptide in the capture ELISA assay showed a highly linear correlation (R2>0.99), confirming that the assay is quantitative (Supplementary Figure 5). Quantification of SMC-derived IL-12Rβ2 in plasma samples of AMI patients by a capture ELISA. (A) Schematic presentation of the sandwich and capture ELISA systems. The SMC-derived EVs were captured from the blood samples by anti-PDGFRβ antibody on the plate and assayed by the biotin-conjugated detection antibodies against PDGFRβ and IL-12Rβ2. (B) Sandwich ELISA assay showing the amount of PDGFRβ in the SMC-derived EVs isolated from the plasma samples (Normal: n=12, SA: n=11, and AMI: n=15). Data in the graphs are means ± SD of colorimetric values at 450 nm. The sample information is summarized in Supplementary Table 1. (C) Capture ELISA assay showing the amount of IL-12Rβ2 in the SMC-derived EVs isolated from the plasma samples (Normal: n=15, SA: n=21, and AMI: n=22). Data in the graphs are means ± SD of colorimetric values at 450 nm. (D) A large-scale analysis of the plasma IL-12Rβ2 level using capture ELISA system. Cohort size, number of positive responders (OD450>0.05), specificity, and sensitivity of the ELISA assay were summarized in the table. Data in the graphs are means ± SD. AMI = acute myocardial infarction; CD81 = cluster of differentiation 81; ELISA = enzyme-linked immunosorbent assay; EV = extracellular vesicle; IL-12Rβ2 = interleukin-12 receptor beta2 subunit; n.s. = not significant; OD = optical density; PDGFRβ = platelet-derived growth factor beta chain; SA = stable angina; SD = standard deviation; SMC = smooth muscle cell. **p<0.01; ****p<0.0001; ####p<0.0005. Collectively, these findings demonstrate that the plasma IL-12Rβ2 integrated to the SMC-derived EVs may serve as a potential biomarker indicating atherosclerotic lesions containing vulnerable plaques. DISCUSSION Direct tissue-based proteomic analysis has been performed using human coronary atherosclerotic plaques.23) The CardioGene study, led by the National Heart, Lung, and Blood Institute, NIH, focused on plasma-based proteomics in patients with in-stent restenosis, rather than analyzing tissue from stented vessels.24) Rodent models, such as ApoE-deficient mice fed a high-fat diet or a surgically-induced injury of rat carotid artery, were also used for proteomics screening.25),26) However, none of the studies have led to clinically validated biomarkers for the prediction or diagnosis of acute coronary syndromes. In our previous differential proteomic analysis using a rat carotid artery restenosis model induced by balloon injury,13) we unexpectedly identified an immune cell receptor called IL-12Rβ2. At first, we dismissed this spot as likely immune cell contamination within carotid tissue preparation. However, during a separate study investigating phenotypic modulation in HASMCs, we incidentally evaluated IL-12Rβ2 expression and discovered that its transcript was present in synthetic-type SMCs. This unexpected finding prompted us to pursue a systematic investigation of IL-12Rb2 expression in HASMCs. Strikingly, IL-12Rβ2 expression was induced specifically by IFN-γ, not by other pro-inflammatory cytokines. Further analyses revealed that the expressed IL-12Rβ2 plays multiple roles in SMCs probably through cooperation with other growth factor and cytokine receptors and in neointimal SMC hyperplasia in vivo. Once before, several studies have indicated that IL-12 affects the proliferation of the synthetic vascular SMCs associated with atherosclerosis.27),28) Thus, our first finding of IL-12Rβ2 expression and function in vascular SMCs provides new insight into SMC biology associated with atherosclerosis and highlights its potential as a novel therapeutic target. A further unexpected finding was the presence of IL-12Rβ2 in the SMC-derived EVs, which were significantly elevated in the plasma samples from AMI patients compared to those from healthy volunteers. Notably, IL-12Rβ2 was not detected in the SMC-derived EVs from SA patients, where medial SMCs are stabilized and not actively proliferating. Clinically, unstable angina (UA) is closely associated with plaque instability and presents as a medical emergency requiring prompt intervention to ensure patient survival. Although UA samples were not analyzed in this study due to limited availability, our plasma analysis strongly suggests that IL-12Rβ2 levels detected in the form of the SMC-derived EVs may be the first blood protein that directly reflects plaque instability leading to AMI. Nevertheless, the cellular mechanism by which IL-12Rβ2 is secreted through EVs remains speculative, and the UA samples were not analyzed in this study due to their limited availability. Therefore, we intend to further investigate the IL-12Rβ2 secretion mechanism and analyze the full spectrum of acute coronary syndromes, including UA patients. Given its pathophysiological relevance, IL-12Rβ2 may serve as a potential biomarker that complements established inflammatory and myocardial biomarkers, such as troponin, BNP, or high sensitivity-CRP.29),30) To support clinical translation, we developed a selective EV-capture ELISA that quantitatively measures plasma IL-12Rβ2 associated with the SMC-derived EVs, isolated using PDGFRβ-specific antibody. This type of capture ELISA platform offers a non-invasive, simple (~3 hours for manual 96-well assay), and cost-effective method for detecting SMC-derived IL-12Rβ2, enabling broader validation studies in large patient cohorts, including those with UA, SA, and AMI. Furthermore, IL-12Rβ2, when combined with established cardiac biomarkers or risk scores (e.g., GRACE, TIMI), may enhance early risk assessment across the spectrum of CVDs. Footnotes Funding: This study was supported by the National Research Foundation of Korea (2017M3A9G2077885) and the Korea Drug Development Fund funded by the Ministry of Science and ICT, the Ministry of Trade, Industry, and Energy, and the Ministry of Health and Welfare (RS-2024-00338193). Conflict of Interest: The authors have no financial conflicts of interest. Data Sharing Statement: The data generated in this study is available from the corresponding authors upon reasonable request. Author Contributions: Conceptualization: Kang SW.Formal analysis: Kang DH, Lee HS, Yang JA.Methodology: Lee HS, Yang JA.Resources: Kang IS, Jung S.Supervision: Kwon K, Kang SW.Validation: Kang DH, Lee HS, Yang JA, Kang IS, Jung S.Writing - original draft: Kang DH, Kang SW.Writing - review & editing: Kwon K, Kang SW. Conceptualization: Kang SW. Conceptualization: Kang SW. Formal analysis: Kang DH, Lee HS, Yang JA. Formal analysis: Kang DH, Lee HS, Yang JA. Methodology: Lee HS, Yang JA. Methodology: Lee HS, Yang JA. Resources: Kang IS, Jung S. Resources: Kang IS, Jung S. Supervision: Kwon K, Kang SW. Supervision: Kwon K, Kang SW. Validation: Kang DH, Lee HS, Yang JA, Kang IS, Jung S. Validation: Kang DH, Lee HS, Yang JA, Kang IS, Jung S. Writing - original draft: Kang DH, Kang SW. Writing - original draft: Kang DH, Kang SW. Writing - review & editing: Kwon K, Kang SW. Writing - review & editing: Kwon K, Kang SW. SUPPLEMENTARY MATERIALS Supplementary Data 1 Methods Supplementary Table 1 Clinical characteristics of study participants in each group Supplementary Figure 1 IL-12Rβ2 upregulation in balloon-injured rat carotid arteries. The membrane fractions from injured rat carotid arteries were separated on 2-dimensional acrylamide gels as described in the Methods section. IL-12Rβ2 was identified as one of the significantly upregulated proteins in the injured arteries. Three-dimensional image analysis of IL-12Rβ2 spot intensity at different time points (0-, 3-, and 7-days post-injury) demonstrates a progressive increase in IL-12Rβ2 expression during vascular remodeling. Quantitative analysis in two-dimensional difference gel electrophoresis further confirms a significant increase in IL-12Rβ2 protein expression at 7 days post-injury. Data are presented as mean ± standard deviation (n=3). Supplementary Figure 2 Analysis of IL-12Rβ2 transcript variants expressed in HASMCs. Supplementary Figure 3 Identification of IL-12Rβ2 in human plasma from AMI patients. Supplementary Figure 4 NTA of plasma EVs isolated from AMI patient using a polymer-based precipitation method. Supplementary Figure 5 Dilution linearity using recombinant fusion protein. Serial 2-fold dilutions of the purified recombinant fusion protein containing the PDGFRβ and IL-12Rβ2 antigenic peptide regions were analyzed under the same ELISA conditions as those used for plasma samples. References Associated Data Supplementary Materials Supplementary Data 1 Methods Supplementary Table 1 Clinical characteristics of study participants in each group Supplementary Figure 1 IL-12Rβ2 upregulation in balloon-injured rat carotid arteries. The membrane fractions from injured rat carotid arteries were separated on 2-dimensional acrylamide gels as described in the Methods section. IL-12Rβ2 was identified as one of the significantly upregulated proteins in the injured arteries. Three-dimensional image analysis of IL-12Rβ2 spot intensity at different time points (0-, 3-, and 7-days post-injury) demonstrates a progressive increase in IL-12Rβ2 expression during vascular remodeling. Quantitative analysis in two-dimensional difference gel electrophoresis further confirms a significant increase in IL-12Rβ2 protein expression at 7 days post-injury. Data are presented as mean ± standard deviation (n=3). Supplementary Figure 2 Analysis of IL-12Rβ2 transcript variants expressed in HASMCs. Supplementary Figure 3 Identification of IL-12Rβ2 in human plasma from AMI patients. Supplementary Figure 4 NTA of plasma EVs isolated from AMI patient using a polymer-based precipitation method. Supplementary Figure 5 Dilution linearity using recombinant fusion protein. Serial 2-fold dilutions of the purified recombinant fusion protein containing the PDGFRβ and IL-12Rβ2 antigenic peptide regions were analyzed under the same ELISA conditions as those used for plasma samples.